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PURPOSE: This study assessed long-term functional
outcome and explored risk factors for fistula recurrence
in patients surgically treated for cryptoglandular fistulas.
METHODS: Three hundred ten consecutive patients were
surgically treated for perianal fistulas. After exclusion of
patients with inflammatory bowel disease or HIV, 179
patients remained. Patients were divided into two groups:
those who received fistulotomy for low perianal fistulas and
those who received rectal advancement flap for high perianal
fistulas. Time to fistula recurrence was the main outcome
and Cox proportional hazard models were used to assess the
importance of various risk factors. Functional outcome was
assessed using the Vaizey and colorectal functional outcome
(COREFO) questionnaires.
RESULTS: The median follow-up duration was 76 months
(range, 7–134). The 3-year recurrence rate for low perianal
fistulas treated by fistulotomy (n=109) was 7 percent
(95 percent confidence interval, 1–13 percent). In high
transsphincteric fistulas treated by rectal advancement flap
(n=70), the recurrence rate was 21 percent (95 percent
confidence interval, 9–33 percent). In both groups, soiling
was reported at 40 percent. None of the seven potential risk
factors examined were statistically significant.
CONCLUSIONS: Fistula recurrence rate after fistulotomy was
low. No clear risk factors were found. Overall functional
outcome in terms of continence was good. However, a
substantial amount of patients reported soiling.
KEY WORDS: Rectal fistula; Surgery; Recurrence;
Continence; Risk factor.
INTRODUCTION
The aim of fistula surgery is to eradicate the fistula tract by
closing the internal opening, without jeopardizing conti-
nence. In general, patients with perianal fistulas in the lower
one-third of the external sphincter complex are easily treated
by fistulotomy with low recurrence rates and relatively little
impact on continence.1,2 For perianal fistulas in the upper
two-thirds of the external sphincter complex, the rectal
advancement flap is considered the standard surgical
treatment. Various treatment options have emerged in recent
years for the treatment of high perianal fistulas. During the
last decades, fibrin glue appeared as an attractive alternative.
Reported long-term outcomes vary considerably between the
different studies and recurrence rates range from 0 to 100
percent.3 Inconsistent reports of recurrence rates are likely a
result of heterogeneous research designs. Often patients with
Crohn’s disease and HIV were included, various classifica-
tions of perianal fistulas were used, alternative treatment
protocols were used, and sufficient follow-up was lacking.
This study examined long-term functional outcome and
assessed possible risk factors for the development of fistula
recurrence in patients surgically treated by fistulotomy or
rectal advancement flap according to a standardized treat-
ment protocol. As the recurrence rate and the continence are
the most important factors in the treatment of perianal
fistulas, these measures were specifically studied.
PATIENTS AND METHODS
Patient Characteristics
Between January 1995 and May 2003, a consecutive series of
patients operated for perianal fistulas of cryptoglandular
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origin were analyzed. Patients in which the internal fistula
opening could not be detected and patients with fistulas
caused by Crohn’s disease or human immunodeficiency
virus (HIV) were excluded, as well as patients aged less than
18 years and patients with rectovaginal fistulas.
Treatment Protocol
Patients were divided into two groups. These groups were
operated on according to a standardized treatment proto-
col. The first group comprised patients in which the fistula
tract was submucosal, intersphincteric, or located in the
lower third of the external anal sphincter and were treated
by fistulotomy (fistulotomy group). The second group
comprised patients with perianal fistula in which the fistula
tract was located in the upper two-thirds of the external
sphincter and who were treated by rectal advancement flap
(rectal advancement flap group). In cases of acute sepsis,
patients were treated with three months of seton drainage
before definitive surgery. The anal canal was defined on the
proximal side by the puborectal sling and the distal side by
the lower margin of the external sphincter. On the day of
surgery, an enema was administered to the patient to clean
the rectum. All procedures were performed under general
or locoregional anesthesia in the lithotomy position. Broad
spectrum antibiotics were administered perioperative. The
rectal advancement flap was performed according to a
technique described herein. The internal opening was
excised followed by mobilization of the mucosa, submu-
cosa, and a small amount of muscular fibers from the
internal sphincter. A rectal flap with a 2-cm to 3-cm broad
base was mobilized. The rectal flap was mobilized
sufficiently to cover the internal opening with overlap.
Hemostasis was performed to prevent a hematoma under
the flap. The fistula tract was curetted. The internal
opening was not closed before advancing the flap over the
internal opening. Finally, the flap was sutured in the distal
anal canal with interrupted Vicryl 2–0 sutures (Ethicon
Endo-Surgery, Cincinnati, OH). In a consecutive series of
patients, fibrin glue was added to the procedure in an
attempt to decrease the recurrence rate. No specific
postoperative instructions or bowel regimens were given
to the patients.
Data Collection
Retrospective chart review collected information on de-
mographic data, tertiary referral, previous fistula surgery,
smoking, surgical treatment (fistulotomy or rectal ad-
vancement flap), complications, and fistula recurrence
rate. Prior fistula surgery was defined as surgery aimed to
permanently repair the fistula. Drainage of abscesses and
seton placement were not considered as prior fistula
surgery. All patients visited the outpatient clinic until
closure of the fistula tract was achieved. The fistula was
considered closed if the external opening was closed and
no discharge or pain was experienced. Otherwise, the
fistulas were considered persistent or recurrent. Follow-
up was calculated from the clinical notes when the patient
did not respond to the postal survey and to multiple
attempts to contact them by telephone. In the question-
naire, patient’s complaints indicated a recurrent fistula.
Patients were asked if they had been operated on
elsewhere after their visits to our clinic.
Functional Outcome
To assess functional outcome of treatment, a postal survey
was undertaken. Patients who did not respond were
contacted by telephone. If patients had moved, the general
practitioner was contacted for their address and telephone
number. Continence was evaluated using the Vaizey scale
and the colorectal functional outcome (COREFO) ques-
tionnaire.4,5 The validated Vaizey scale consisted of items
on the type and frequency of incontinence. Also, changes
in lifestyle were assessed. Patients are asked on their use of
pads or plugs, constipation medication, and the lack of
ability to postpone defecation for 15 minutes. The total
score on Vaizey scale ranged from 0 (complete continence)
to 24 (complete incontinence). The COREFO question-
naire is a validated questionnaire with 27 questions to
assess colorectal functional outcome. Patient’s were asked
to consider the two weeks prior before filling out the
questionnaire. Five categories were assessed: incontinence,
social impact, defecation frequency, stool-related aspects
(questions on pain during bowel movements, blood loss,
and local skin problems), and use of medication. Scores
ranged from 0 to 100. A total score was calculated from
these categories, also ranging from 0 to 100. A higher score
represents an increased level of continence disturbance. In
the same survey, patients were asked about smoking habits
and whether they had fistula surgery in another hospital
after discharge.
Statistical Analysis
Data are presented as median values with ranges unless
otherwise specified. Categorical data are presented as
frequencies or percentages. Differences between groups
were tested using Mann-Whitney U test for continuous
data. Chi-squared test was used to test for differences
between groups in cases of categorical data. Fistula
recurrence-free survival was estimated using the Kaplan-
Meier method. Cox proportional hazard models were used
to examine the association between potential risk factors
and the time until fistula recurrence. Hazard ratios (HR)
with 95 percent confidence intervals were used to quantify
the strength of these associations.6 The following potential
risk factors were examined: gender, age, tertiary referral,
prior fistula surgery, and smoking. For the rectal advance-
ment flap group, the factors seton drainage and the use of
fibrin glue were also examined. Natural cubic splines (4
knots) graphical analysis were used to examine the
functional form of continuous variables in relation to the
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outcome.7,8 Based on these graphic analyses, an appropri-
ate transformation or categorization was chosen if the
relationship was clearly nonlinear. P<.05 was considered
as statistically significant. Statistical analysis was done using
the SPSS v.12.0 package (SPSS, Chicago, IL).
RESULTS
Between January 1995 and May 2003, 310 patients were
operated on for perianal fistulas in the study period. Patients
were excluded (N=131) for the following reasons: no
internal opening found during surgery (n=8), HIV (n=
23), rectovaginal fistulas (n=22), or inflammatory bowel
disease (n=78) (Fig. 1). Of the remaining 179 patients, 109
patients had low fistulas and were treated by fistulotomy. The
remaining 70 patients had high perianal fistulas and were
treated by rectal advancement flap. The majority of patients
had outpatient surgery. The minimum observed follow-up
for all patients after surgery was 7 months with a median of
76 months (range, 7–134). Seventy-nine of 179 patients
could not be contacted by mail or telephone because they
had moved without informing their general practitioner or
because they were deceased. These patients were censored at
their date of last clinical contact at which they had no sign of
recurrence. The response rate for 100 patients successfully
contacted by mail or telephone was 95 percent.
Fistulotomy Group
The median age was 39 years (range, 19–69) (Table 1).
Seventy-one patients were male (65 percent). Prior fistula
surgery was performed in 22 patients (20 percent).
Fourteen patients (13 percent) were referred from other
hospitals mainly because of complex and or recurrent
fistulas. The median number of previous surgical proce-
dures was 1 (range, 0–5). Patients had fistula-related
complaints for a median of 6 months (range, 0–240).
Preoperative continence was impaired in three patients
and varied from incontinence of flatus to soiling,
determined by medical history on the initial visit to the
outpatient clinic. At the time of surgery, 32 percent of the
patients smoked. A postoperative complication was
encountered in 2 patients: minor bleeding (n=1) and
urinary tract infection (n=1). The 3-year recurrence rate
was 7 percent (n=8, 95 percent CI, 1–13 percent, Fig. 2)
The data on the continence questionnaires completed by
63 patients are presented in Table 2. The median follow-
up duration of patients with completed questionnaires
was 74 months (range, 7–134). The mean total Vaizey
score was 6.5 (SD, 3.5) and 18 of 63 (29 percent) had
perfect continence (Vaizey score=0). The mean total
score for the COREFO questionnaire was 9.8 (SD, 12.4).
The mean incontinence scale was 9.2 (SD, 12.8). Soiling
was reported in 26 of 63 patients (41 percent). Only three
patients reported having lost solid stool unintentionally.
None of the potential risk factors for fistula recurrence
reached statistical significance in the univariate or in the
multivariate analysis (Table 3). In male patients that
smoked and were referred to a tertiary center, the estimated
risk for fistula recurrence was more than doubled, but the
associated confidence intervals were wide.




n = 310 123 Excluded because of:
•  78 Crohn’s Disease
•  23 HIV
•  22 Rectovaginal fistula
8 Excluded because of:




























Male: Female, n 71:38 47:23
Age, years, median (range) 39 (19–69) 42 (21–67)
Tertiary referral n (%) 14 (13%) 27 (39%)
Prior fistula surgery, n (%)
0 87 (80%) 37 (53%)
1 13 (12%) 17 (24%)
2 5 (5%) 6 (9%)
3 or more 4 (4%) 10 (14%)




Fibrin glue addition, n (%) − 16 (23%)
Seton drainage, n (%) − 37 (39%)
Recurrence, n (%) 8 (7%) 15 (21%)
Follow-up, months,
median (range)
77 (7–134) 70 (22–127)
* Low perianal fistulas  † High perianl fistulas
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Rectal Advancement Flap Group
The median age at the time of surgery was 42 years
(range, 21–67). Forty-seven patients were male (67
percent). Twenty-nine patients (41 percent) had under-
gone prior fistula surgery (Table 1). Twenty-seven
patients (39 percent) were referred from other hospitals
because of complex and/or recurrent fistulas. The median
number of previous surgical procedures was 2 (range,
0–8). Patients had fistula-related complaints for a median
of 12 months (range, 1−144). Preoperative continence was
disturbed in seven patients. Four of these patients were
incontinent for flatus and the three others had soiling. At
the time of surgery, 43 percent of patients smoked. Before
performing the rectal advancement flap procedure, 37
patients (39 percent) were treated by seton drainage. In 16
patients, fibrin glue was added to the procedure. In two
patients a postoperative complication was encountered:
minor bleeding (n=1) and bradycardia for which the
patient was observed overnight (n=1, patient with cardiac
history). The recurrence rate for fistulas treated by rectal
advancement flap was 21 percent (n=15, 95 percent CI,
9–33 percent, Fig. 2). The outcome of patients with seton
drainage did not significantly differ from the patients
without. In the patients that underwent seton drainage,
the recurrence rate (24 percent) was similar to patients
without seton drainage (18 percent, P=0.53). In the group
of patients that underwent rectal advancement flap
combined with fibrin glue, the fistula recurrence rate was
31 percent similar to the advancement only group at 17
percent (P=0.31). A median of 2 operations was necessary
in these patients to close the persistent fistulas (range, 2–4).
In 37 of 39 successfully contacted patients, the continence
questionnaires were completed (Table 2). The median
follow-up duration of patients with completed question-
naires was 64 months (range, 22–126). The mean total
Vaizey score was 6.2 (SD, 4.0). Of 37 patients, 2 (5 percent)
had a perfect continence (Vaizey score=0). The mean total
score for the COREFO questionnaire was 10.8 (SD, 11.2).
The mean incontinence scale was 11.8 (SD, 13.6). Sixteen
of 37 (43 percent) patients reported soiling. Only two
patients reported problems with losing solid stool unin-
tentionally. In the rectal advancement flap treatment
group, none of the potential risk factors reached statistical
significance, neither in the univariate nor in the multivar-
iate analysis (Table 4).
DISCUSSION
This retrospective study assessed the long-term results of
surgical treatment of a large consecutive series of patients
with low or high perianal fistulas of cryptoglandular origin
treated according to a standardized treatment protocol. In
the present series of patients treated by fistulotomy or
rectal advancement flap, the observed recurrence rate was 7
and 21 percent respectively at a median follow-up of
76 months. The overall functional outcome measured by
the COREFO and the Vaizey scale was not significantly
different from normal patients.5 However, around 40
percent of the patients in both groups were found to have
problems with soiling, which is considerable. No signifi-
cant risk factors for the development of a recurrent
perianal fistula were found in either the fistulotomy or
the rectal advancement flap treatment group with either
univariate or multivariate analysis.
Table 2. Vaizey scale and colorectal functional outcome













Incontinence 1.9 (3.4) 2.0 (2.5) 2.3 (2.8)
Social impact 9.5 (3.5) 4,5 (1.7) 3.9 (2.5)
Total 5.6 (2.8) 6.5 (3.5) 6.2 (4.0)
COREFO¶
Incontinence
range 5.6 (7.5) 9.2 (12.8) 11.8 (13.6)
Social impact 9.2 (11.0) 9.7 (13.9) 12.3 (12.3)
Frequency 6.2 (8.8) 7.7 (12.9) 6.4 (6.4)
Stool-related
aspects 7.7 (12.9) 14.4 (19.9) 12.6 (12.6)
Medication 6.1 (15.6) 8.2 (18.0) 5.9 (14.9)
Total 7.2 (7.0) 9.8 (12.4) 10.8 (11.2)
* Group of control patients after right-sided hemicolectomy or laparoscopic
cholecystectomy5  †Low perianal fistulas (amount returned questionnaires), ‡High
perianal fistulas (amount returned questionnaires). §Mean score ranging from 0–24
(complete continence-complete incontinence) for the total score. Both subscale scores
range from 0–12.  ¶Mean score per category after linear transformation to a score from
0–100, higher score represents an increased level of continence disturbance. As the













FIGURE 2. Fistula recurrence-free survival after fistulotomy (n=109
patients) and rectal advancement flap (n=70).
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The recurrence rate found in the present study conforms
with recurrence rates reported in the literature, which
range from 0 to 39 percent.9,10 This wide range is a result
of the heterogeneous population selected for fistulotomy
in the different studies, which makes it difficult to
compare the different outcomes. In a recent series from
Van de Hagen et al., 62 patients with a fistula tract
originating from the lower third of the anal sphincter
were treated by simple fistulotomy. At a median follow-
up of 75 months, a cumulative recurrence of 39 percent
was found. In the series, patients with Crohn’s disease
also were included. These nine patients with Crohn’s
disease had a cumulative recurrence rate of 60 percent at a
follow-up of 48 months.10 Patients with perianal fistulas
caused by Crohn’s disease should therefore be assessed
separately because of the origins of the disease and
because outcome depends on the presence of proctitis.11
The recurrence rate found in the present study for the
rectal advancement flap is relatively favorable to the
literature, in which success rates are reported between 40
and 90 percent.12–14 These results account for a select
patient group where patients with HIV, Crohn’s disease,
and inability to find the internal opening were excluded.
These recurrence rates however remain relatively high. In
our study, 1 in 5 patients needed multiple operations to
successfully treat high fistulas. In this series of patients
treated with fibrin glue in addition to the rectal
advancement flap, no significant differences in procedure
success rate were observed. However, several other
authors found the addition to be deleterious for the
closure of the fistula in combination with the advance-
ment flap.15,16
Unfortunately, from a substantial number of patients,
no questionnaires were received. To maximize the response
rate all patients that failed to return the questionnaires were
contacted by telephone. Furthermore, if the patients had
moved, their general practitioner was contacted for their
address and telephone number. This effort resulted in only
five patients that refused to respond by telephone. Since our
response rate was only 53 percent and no detailed
preoperative data on continence was available, there is a
potential error in the outcome and conclusions drawn.
Disruption of the sphincter complex leads to incon-
tinence.17 The COREFO questionnaire and Vaizey scale
were used in this study for the continence assessment. In
both groups, overall continence outcomes were not
significantly different from normal. The scores found
were comparable to the scores reported by Bakx et al. for
a group of control patients without complaints after right-
sided hemicolectomy or laparoscopic cholecystectomy.5
In the subscales, stool aspects and incontinence, our
sample had slightly worse scores than in the control
group.5 The subscale, stool aspects, contains questions on
blood loss during bowel movement and having irritated
perianal skin. Around 25 percent of the patients who
received fistulotomy or rectal advancement flap reported
problems in stool aspects. The subscale, incontinence,
implies patients having problems ranging from having to
use pads to protect underwear to unintentionally passing
stools. When looking in detail at soiling, a considerable
amount of patients had problems postsurgery. This
finding was surprising given the rectal advancement flap
is considered a sphincter-saving procedure. These data
indicate that soiling is a considerable problem after
Table 4. Rectal advancement flap group: possible risk factors for fistula recurrence
Simple model
HR (95% CI) P-value
Multivariate HR
(95% CI) P-value
Male sex 1.16 (0.40–3.39) 0.79 1.35 (0.44–4.12) 0.60
Age (per 10 years increase) 0.70 (0.39–1.28) 0.25 0.67 (0.35–1.27) 0.16
Tertiary referral 1.66 (0.60–4.58) 0.33 1.60 (0.50–5.11) 0.39
Prior fistula surgery 1.16 (0.41–3.28) 0.77 1.38 (0.38–5.03) 0.87
Smoking 1.52 (0.54–4.26) 0.43 1.15 (0.39–3.44) 0.69
Seton drainage 1.54 (0.53–4.51) 0.43 1.58 (0.52–4.78) 0.42
Fibrin glue 1.55 (0.55–4.36) 0.41 1.35 (0.42–4.31) 0.61
HR = Hazard Ratio  CI = Confidence Interval
Table 3. Fistulotomy group: possible risk factors for fistula recurrence
Simple model HR (95% CI) P-value Multivariate HR (95% CI) P-value
Male sex 3.74 (0.46–30.47) 0.22 3.83 (0.46–32.21) 0.22
Age (per 10 years increase) 0.73 (0.33–1.58) 0.42 0.83 (0.39–0.18) 0.61
Tertiary referral 3.85 (0.92–16.12) 0.07 2.81 (0.51–15.35) 0.23
Prior fistula surgery 1.54 (0.37–6.44) 0.55 1.40 (0.32–6.18) 0.66
Smoking 2.20 (0.53–9.21) 0.28 1.67 (0.31–9.15) 0.55
HR = Hazard Ratio  CI = Confidence Interval
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surgery for fistula, although it is not clear whether the
soiling problem was solely the result of surgery since no
preoperative data on soiling were available for comparison.
Furthermore, the number of prior surgical procedures was
high in the rectal advancement flap treatment group.
The question arises as to what extent this relatively
young population will develop continence problems in
the future. In the literature, many different criteria are
used to report incontinence and as a consequence the
continence outcome varies substantially between different
publications.18,19 Further prospective research is needed
to assess long-term outcome of continence after different
treatments for perianal fistulas using validated question-
naires before and after surgery.
In the risk factor analysis, tertiary referral in the
fistulotomy group showed a trend toward significance
(P=0.065) and displayed a clinically significant absolute
effect size (HR=3.74). However, the confidence interval is
large, possibly because of a small sample size, which limits
the interpretation of these results. An explanation for this
large effect size seen for tertiary referral may be that most
patients requiring simple fistulotomy are not referred to
tertiary centers. Possibly these patients had complex fistula
which were expected by their physician to lead to recur-
rence. Unfortunately, as a result of the retrospective nature
of this study, further data were not available.
Garcia-Aguilar et al. described risk factors for recur-
rence in a series of patients with anorectal fistulas of
cryptoglandular origin with the use of a mailed question-
naire. Prior fistula surgery was not found to be significantly
associated with recurrence, however a clear trend was
described.20 In a retrospective study of 106 advancement
flap procedures by Mizrahi et al., prior attempts at fistula
repair were not associated with recurrence. However,
Crohn’s disease appeared to be correlated to fistula
recurrence.21
Smoking is well known to influence wound healing in
various patient groups.22,23 In the literature, smoking was
assessed as a possible risk factor and discrepancies exist as
to whether smoking has an effect on the outcome of
surgical treatment for anorectal fistulas. Zimmermann et
al. described smoking to be associated with a high risk for
fistula recurrence in 105 patients with perianal fistulas of
cryptoglandular origin treated with a rectal advancement
flap. A reduced blood flow in the flap was noted as a
possible contributing factor.24 Recently, Gustafsson et al.
did not find any relationship between smoking and a
lower healing rate in their randomized trial of 83 patients
surgically treated by rectal advancement flap for high
anorectal fistulas.25 In the present study, no significant
relationship could be found between smoking and fistula
recurrence as well.
CONCLUSION
This study assessed long-term outcome of two distinctive
groups of patients with perianal fistulas of cryptogland-
ular origin. The recurrence rate was low in the group
treated by fistulotomy. In patients treated with rectal
advancement flap procedure for high perianal fistulas, a
considerable number of recurrences occurred. No clear
risk factors for the development of a recurrent perianal
fistula were found in the fistulotomy nor in the rectal
advancement flap treatment group. Overall, continence
disturbances were infrequent and similar in both groups.
However, a reasonable number of patients in both groups
reported soiling. Further research is warranted to develop
new techniques to deal with high perianal fistulas of
cryptoglandular origin and to solve the probable high
incidence of soiling.
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